• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Bock Thomas was granted 400,000 units of Ordinary Shares (SEC Form 4)

    5/10/24 5:04:42 PM ET
    $NTBL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NTBL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Bock Thomas

    (Last) (First) (Middle)
    C/O NOTABLE LABS, LTD.
    320 HATCH DRIVE

    (Street)
    FOSTER CITY CA 94404

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Notable Labs, Ltd. [ NTBL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/08/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Ordinary Shares 05/08/2024 A 400,000 A $0(1) 400,000 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options $1.19 05/08/2024 A 150,000 (2) 05/08/2034 Ordinary Shares 150,000 $0 150,000 D
    Explanation of Responses:
    1. Grant of restricted shares vesting in four equal annual installments from the date of grant.
    2. Vests in equal annual installments over a two-year period from the date of grant.
    /s/ Thomas Bock 05/10/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NTBL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTBL

    DatePrice TargetRatingAnalyst
    9/20/2024Mkt Outperform → Mkt Perform
    JMP Securities
    More analyst ratings

    $NTBL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Notable Labs to Present Data on September 4th at SOHO 2024

      Society of Hematologic Oncology (SOHO) session to highlight volasertib program Phase 2 volasertib AML program expected to begin in the coming months FOSTER CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that the Company will present an overview of the Phase 2 program and additional data from preclinical studies evaluating volasertib for acute myeloid leukemia (AML) at the twelfth annual meeting of the Society for Hematologic Oncology (SOHO 2024), b

      8/29/24 7:30:00 AM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notable Labs Announces CEO Transition

      Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that Thomas A. Bock, MD has resigned from his positions as Chief Executive Officer (CEO) and member of the Board of Directors of the Company, effective today. Joseph Wagner, PhD, the Company's Chief Scientific Officer (CSO), has been appointed as interim CEO. T

      8/26/24 4:05:00 PM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

      FOSTER CITY, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), today announced progress for the Phase 2 volasertib program following receipt of "Clearance to Proceed" from the FDA and agreement on the dosing plan for its Phase 2 clinical trial. With trial start-up activities launched in the first quarter of this year, Notable intends to initiate enrollment in the Phase 2 study for PMP-enabled development of volasertib for relapsed refractory (R/R) acute myeloid leukemia (AML) in the coming mo

      7/24/24 7:30:00 AM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTBL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Notable Labs Ltd.

      SC 13D/A - Notable Labs, Ltd. (0001603207) (Subject)

      8/9/24 4:01:56 PM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTBL
    Leadership Updates

    Live Leadership Updates

    See more
    • Notable Labs Announces CEO Transition

      Thomas Bock, MD resigns as CEO; Joseph Wagner, PhD, CSO, appointed interim CEO Company affirms plan to initiate volasertib Phase 2 program in the coming months FOSTER CITY, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable", "Notable Labs" or the "Company"), a clinical-stage precision oncology company developing new cancer therapies identified by its Predictive Medicine Platform (PMP), announced that Thomas A. Bock, MD has resigned from his positions as Chief Executive Officer (CEO) and member of the Board of Directors of the Company, effective today. Joseph Wagner, PhD, the Company's Chief Scientific Officer (CSO), has been appointed as interim CEO. T

      8/26/24 4:05:00 PM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTBL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Notable Labs downgraded by JMP Securities

      JMP Securities downgraded Notable Labs from Mkt Outperform to Mkt Perform

      9/20/24 7:46:25 AM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTBL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Zagger Kaile A. claimed no ownership of stock in the company (SEC Form 3)

      3 - Notable Labs, Ltd. (0001603207) (Issuer)

      9/26/24 11:07:19 AM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Patsi Tuomo was granted 65,247 units of Ordinary Shares (SEC Form 4)

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      5/10/24 5:18:35 PM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Wagner Joseph P

      4 - Notable Labs, Ltd. (0001603207) (Issuer)

      5/10/24 5:17:04 PM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $NTBL
    SEC Filings

    See more
    • Notable Labs Ltd. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Notable Labs, Ltd. (0001603207) (Filer)

      10/16/24 4:30:30 PM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notable Labs Ltd. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update

      8-K - Notable Labs, Ltd. (0001603207) (Filer)

      10/15/24 6:13:51 AM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notable Labs Ltd. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities

      8-K - Notable Labs, Ltd. (0001603207) (Filer)

      9/19/24 4:05:18 PM ET
      $NTBL
      Biotechnology: Pharmaceutical Preparations
      Health Care